Extracorporeal therapy of sepsis by purified granulocyte concentrates-ex vivo circulation model

被引:3
|
作者
Klinkmann, Gerd [1 ,6 ]
Wild, Thomas [2 ]
Heskamp, Benjamin [2 ]
Doss, Fanny [2 ]
Doss, Sandra [2 ,3 ]
Milej, Magdalena [2 ]
Thiele, Lea-Marie [4 ]
Goudeva, Lilia [5 ]
Blasczyk, Rainer [5 ]
Reuter, Daniel A. [1 ]
Altrichter, Jens [2 ]
Mitzner, Steffen [3 ,4 ]
机构
[1] Univ Rostock, Dept Anaesthesiol Intens Care Med & Pain Therapy, Rostock, Germany
[2] ARTCLINE GmbH, Rostock, Germany
[3] Fraunhofer Inst Cell Therapy & Immunol, Dept Extracorporeal Immunomodulat, Rostock, Germany
[4] Univ Rostock, Med Fac, Dept Med, Div Nephrol, Rostock, Germany
[5] Hannover Med Sch, Inst Transfus Med & Transplant Engn, Hannover, Germany
[6] Univ Med Ctr Rostock, Dept Anesthesiol Intens Care Med & Pain Therapy, Schillingallee 35, D-18057 Rostock, Germany
关键词
clinical use; extracorporeal therapy; granulocyte concentrate; sepsis; SEPTIC SHOCK; IMMUNE SUPPORT; IRRADIATION; FILGRASTIM; MANAGEMENT; EXPRESSION; STORAGE;
D O I
10.1111/aor.14507
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Background: Immune cell dysfunction is a central part of immune paralysis in sepsis. Granulocyte concentrate (GC) transfusions can induce tissue damage via local effects of neutrophils. The hypothesis of an extracorporeal plasma treatment with granulocytes is to show beneficial effects with fewer side effects. Clinical trials with standard GC have supported this approach. This ex vivo study inves-tigated the functional properties of purified granulocyte preparations during the extracorporeal plasma treatment.Methods: Purified GC were stored for up to 3 days and compared with standard GC in an immune cell perfusion therapy model. The therapy consists of a plasma separation device and an extracorporeal circuit. Plasma is perfused through the tubing system with donor immune cells of the GC, and only the treated plasma is filtered for re-transfusion. The donor immune cells are retained in the extracor-poreal system and discarded after treatment. Efficacy of granulocytes regarding phagocytosis, oxidative burst as well as cell viability and metabolic parameters were assessed.Results: In pGC, the metabolic surrogate parameters of cell functionality showed comparable courses even after a storage period of 72 h. In particular, glucose and oxygen consumption were lower after extended storage. The course of lactate dehydrogenase concentration yields no indication of cell impairment in the ex-tracorporeal circulation. The cells were viable throughout the entire study period and exhibited preserved phagocytosis and oxidative burst functionality.Conclusion: The granulocytes demonstrated full functionality in the 6 h extra-corporeal circuits after 3 days storage and in septic shock plasma. This is demon-strating the functionality of the system and encourages further clinical studies.
引用
收藏
页码:1151 / 1162
页数:12
相关论文
共 50 条
  • [41] Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I
    Overturf, K
    Al-Dhalimy, M
    Manning, K
    Ou, CN
    Finegold, M
    Grompe, M
    HUMAN GENE THERAPY, 1998, 9 (03) : 295 - 304
  • [42] Differential response to antibiotic therapy in staphylococcal infective endocarditis: contribution of an ex vivo model
    Lalanne, Sebastien
    Cattoir, Vincent
    Guerin, Francois
    Verdier, Marie-Clemence
    Revest, Matthieu
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (07) : 1689 - 1693
  • [43] A large preclinical animal model to assess ex vivo skin gene therapy applications
    Pfuetzner, Wolfgang
    Joari, Mohammed R.
    Foster, Ruth-Ann
    Vogel, Jonathan C.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2006, 298 (01) : 16 - 22
  • [44] Pharmacological Enhancement of ex vivo Gene Therapy Neuroprotection in a Rodent Model of Retinal Degeneration
    Gregory-Evans, Kevin
    Po, Kelvin
    Chang, Francis
    Gregory-Evans, Cheryl Y.
    OPHTHALMIC RESEARCH, 2012, 47 (01) : 32 - 38
  • [45] Ex vivo Gene Therapy in a Mouse Model of Leukocyte Adhesion Deficiency Type I
    Almarza, E.
    Leon-Rico, D.
    Aldea, M.
    Sanchez, R.
    Thrasher, A. J.
    Bueren, J. A.
    HUMAN GENE THERAPY, 2014, 25 (11) : A40 - A41
  • [46] A large preclinical animal model to assess ex vivo skin gene therapy applications
    Wolfgang Pfützner
    Mohammed R. Joari
    Ruth-Ann Foster
    Jonathan C. Vogel
    Archives of Dermatological Research, 2006, 298 : 16 - 22
  • [47] Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation
    Skrzypchak, Amy M.
    Lafayette, Nathan G.
    Bartlett, Robert H.
    Zhou, Zhengrong
    Frost, Megan C.
    Meyerhoff, Mark E.
    Reynolds, Melissa M.
    Annich, Gail M.
    PERFUSION-UK, 2007, 22 (03): : 193 - 200
  • [48] Chromatin profiles from ex vivo purified dopaminergic neurons establish a promising model to support studies of neurological function and dysfunction
    McClymont, S. A.
    Hook, P. W.
    Goff, L. A.
    McCallion, A.
    HUMAN GENOMICS, 2016, 10
  • [49] Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo
    Willem A Marsman
    Christianne J Buskens
    John G Wesseling
    G Johan A Offerhaus
    Jacques JGHM Bergman
    Guido NJ Tytgat
    J Jan B van Lanschot
    Piter J Bosma
    Cancer Gene Therapy, 2004, 11 : 289 - 296
  • [50] Antimicrobial Disposition During Pediatric Continuous Renal Replacement Therapy Using an Ex Vivo Model
    Purohit, Prashant J.
    Elkomy, Mohammed H.
    Frymoyer, Adam
    Sutherland, Scott M.
    Drover, David R.
    Hammer, Gregory B.
    Su, Felice
    CRITICAL CARE MEDICINE, 2019, 47 (09) : E767 - E773